Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets branded, generic, and over-the-counter products. The company operates through five reportable segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Its portfolio focuses on therapeutic areas including gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and eye health. Key products include Xifaxan for irritable bowel syndrome and hepatic encephalopathy, Relistor for opioid-induced constipation, and Trulance for chronic idiopathic constipation. Through its controlling interest in Bausch + Lomb, the company offers vision care, surgical, and pharmaceutical products, including contact lenses and intraocular lenses. Solta Medical provides aesthetic medical devices globally. The company markets its products directly or indirectly in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In September 2025, the company acquired DURECT Corporation, a biopharmaceutical firm specializing in epigenetic therapies for conditions such as alcohol-associated hepatitis. Bausch Health continues to evaluate the separation of its Bausch + Lomb eye health business into an independent publicly traded entity.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage bauschhealth.com
Sector Healthcare IR page ir.bauschhealth.com
Tags
gastroenterology, hepatology, neurology, dermatology, aesthetic medical devices, eye health, contact lenses, intraocular lenses, branded pharmaceuticals, generic pharmaceuticals, over-the-counter products, epigenetic therapies, Salix, International, Solta Medical, Diversified, Bausch + Lomb, Xifaxan, Relistor, Trulance, DURECT, Larsucosterol, Bausch + Lomb Vision Care, Bausch + Lomb Surgical, Bausch + Lomb Pharmaceuticals
Press page bauschhealth.com/news-room/news-releases

Metrics

Valuation  
Market cap $ 2.182B
Market cap (USD) $ 2.182B
P/E -2.55
PEG —
P/BV -1.64
P/S 0.20
P/OCF 0.99
P/FCF 1.17
Dividend yield 22.0%
Turnover / mcap —
Returns  
ROE -28.3%
ROI 0.77%
ROIC 4.5%
Profit margin 1.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 15.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 10.266B 9.625B 8.757B 8.124B 8.434B 8.027B 8.601B 8.38B 8.724B 9.674B 10.447B 8.264B 5.77B 3.547B 2.463B 1.181B 820.43M 757.178M
Net profit 157M -46M -592M -225M -948M -559M -1.783B -4.144B 2.404B -2.408B -287.8M 912.2M -863.669M 882.291M 720.652M -208.193M 176.455M 199.904M
Free cash flow 1.003B 1.26B 817M -946M 1.157B 809M 1.231B 1.344B 2.119B 1.852B 1.965B 2.003B 926.638M 548.94M 617.958M 246.368M 353.474M 182.326M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 6.95 8.06 8.02 6.28 27.61 20.8 29.92 18.47 — 24.72 — — — — — — — —
Price performance 12m -0.14 0 0.28 -0.77 0.33 -0.3 0.62 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 2.52B 2.13B 1.87B 1.84B 1.58B 1.78B 1.79B 2B 2.14B 2.35B
↳ YoY growth -6.3% -15.4% -12.4% -1.4% -14.2% +12.6% +0.8% +11.6% +7.1% +9.9%
↳ 5y CAGR +40.0% +22.6% +2.2% -2.4% -10.1% -6.7% -3.4% +1.4% +3.1% +8.3%
Borrowings, current (USD) 7M 209M 228M 1.23B 0.00 0.00 432M 450M 2.67B 225M
Borrowings, non-current (USD) 29.8B 25.2B 24.1B 24.7B 23.9B 22.7B 20.3B 21.9B 18.9B 20.6B
Lease liabilities (USD) — — 302M 293M 279M 264M 234M 209M 223M 228M
Cash and deposits (USD) 542M 720M 721M 3.24B 605M 582M 564M 947M 1.18B 1.31B
Intangible assets (USD) 18.9B 15.2B 12B 10.2B 8.45B 6.95B 5.8B 6.46B 5.55B 4.64B
Right-of-use assets (USD) — — 302M 271M 259M 247M 221M 185M 211M 215M
Net debt (borrowings + leases - cash) (USD) 29.3B 24.7B 23.6B 22.9B 23.6B 22.3B 20.4B 21.7B 20.7B 19.7B
Cash flow detail
Operating cash flow (USD) 2.09B 2.29B 1.5B 1.5B 1.11B 1.43B -728M 1.03B 1.6B 1.4B
Purchases of property, plant and equipment (USD) -235M -171M -157M -270M -302M -269M -218M -215M -337M -397M
Purchases of intangible assets (USD) -56M -165M -78M -8M -7M -14M -50M -57M -3M -10M
Change in receivables (cash effect) (USD) -34M 417M 216M 39M 170M -229M -57M -195M -216M -134M
Change in inventories (cash effect) (USD) -164M 7M -5M -209M -77M -16M -198M -322M -267M -12M
Change in payables (cash effect) (USD) -144M 387M -121M -149M -471M 121M -75M 158M 357M -76M
Share buybacks (cash effect) (USD) 0.00 0.00 — — — — — — — —
Interest paid (cash effect) (USD) -1.72B -1.71B -1.67B -1.54B -1.47B -1.42B -1.54B -1.53B -1.67B -1.81B
Income taxes paid (cash effect) (USD) -149M -179M -138M -172M -162M -240M -266M -237M -61M -163M
Share-based compensation (USD) 165M 87M 87M 102M 105M 128M 126M 132M 150M 216M
Operating cash flow before change in receivables (USD) 2.12B 1.87B 1.29B 1.46B 941M 1.66B -671M 1.23B 1.81B 1.53B
Free cash flow (OCF - PPE - intangibles) (USD) 1.8B 1.95B 1.27B 1.22B 802M 1.14B -996M 760M 1.26B 993M
Income detail
Research and development expense (USD) 421M 361M 413M 471M 452M 465M 529M 604M 616M 629M
↳ 5y CAGR +45.0% +35.5% +21.4% +13.9% +6.2% +2.0% +7.9% +7.9% +5.5% +6.8%
Total comprehensive income (USD) -2.98B 2.62B -4.39B -1.73B -604M -1.07B -468M -441M -354M 516M
Comprehensive income to owners (USD) -2.98B 2.62B -4.39B -1.74B -607M -1.08B -494M -417M -344M 576M
Provision for credit losses (USD) — — 4M 10M 2M -2M 5M 5M 4M 10M
Credit cost ratio (credit losses / average receivables) (%) — — 0.2% 0.5% 0.1% 0.1% 0.3% 0.3% 0.2% 0.4%
Reported Mar 1, 2017 Feb 28, 2018 Feb 24, 2021 Feb 24, 2021 Feb 24, 2021 Feb 23, 2022 Feb 23, 2023 Feb 22, 2024 Feb 20, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Bausch Health Announces US$50 Million Share Repurchase Program Bull 2 Bear 0 Capital return

Share

facebook googleplus twitter linkedin

Bausch Health Announces US$50 Million Share Repurchase Program

October 28, 2026

Bausch Health Announces US$50 Million Share Repurchase Program

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price of up to US$50 million (the "Share Repurchase Program").

The primary objective of the Share Repurchase Program is to manage the potential dilutive impact of future employee equity-based compensation.

Purchases under the Share Repurchase Program may commence on November 3, 2026, and the Share Repurchase Program will terminate no later than November 3, 2027. Purchases may be made in the open market on the New York Stock Exchange and other published markets in the United States. The Share Repurchase Program is being conducted in reliance on the exemption set forth in section 4.8(3) of National Instrument 62-104 Take-Over Bids and Issuer Bids.

Common Shares will be purchased at the prevailing market price at the time of purchase, subject to a maximum price established by the Board of Directors. The value of any purchases in Canadian dollars will depend on the market price and the applicable exchange rate at the time of each purchase.

The actual number of Common Shares repurchased, and the timing and price of any repurchases, will depend on market conditions, applicable legal requirements and other factors. The Company will not repurchase more than 5% of the 374,266,716 Common Shares outstanding as of October 23, 2026. The Company is not obligated to acquire any particular number of Common Shares, and the Share Repurchase Program may be suspended, modified or discontinued at any time. All Common Shares acquired under the Share Repurchase Program will be cancelled.

**About Bausch Health
**Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com  and connect with us on LinkedIn.

**Forward-looking Statements
**This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact: Media Contact:
Garen Sarafian Alexis Navratil
[email protected] [email protected]
(877) 281-6642 (toll free) (848) 264-0934
BHC- FINANCIAL

Bausch Health logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-us50-million-share-repurchase-program-302922572.html

SOURCE Bausch Health Companies Inc.

<< Back to News Releases

Investor Inquiries
[email protected]

877-281-6642
514-856-3855 (Canada)

Media inquiries
[email protected]

848-264-0934

linkedIn Icon

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION **

Powered by Sitecore

Share

facebook googleplus twitter linkedin

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

October 28, 2026

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643 million of aggregate principal amount of its outstanding 8.500% Senior Notes due 2027, CUSIP Nos. 91911XAW4 and U9098VAP7 (the "Notes"), using cash on hand. The redemption date is November 30, 2026. The notice of redemption will be issued to the record holders of such Notes. Nothing contained herein shall constitute a notice of redemption of the Notes. Payment of the redemption price and surrender of the Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the U.S. paying agent are as follows: The Bank of New York Mellon, 240 Greenwich Street, Floor 7E, New York, New York 10286; Attn: Corporate Trust Administration. In connection with the redemption, the indenture pursuant to which the Notes were issued will be terminated.

**About Bausch Health
**Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com  and connect with us on LinkedIn.

**Forward-looking Statements
**This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact: Media Contact:
Garen Sarafian Alexis Navratil
[email protected] [email protected]
(877) 281-6642 (toll free) (848) 264-0934
BHC-FINANCIAL

Bausch Health logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-full-redemption-of-8-500-senior-notes-due-2027--302922569.html

SOURCE Bausch Health Companies Inc.

<< Back to News Releases

Investor Inquiries
[email protected]

877-281-6642
514-856-3855 (Canada)

Media inquiries
[email protected]

848-264-0934

linkedIn Icon

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION **

Powered by Sitecore

Share

facebook googleplus twitter linkedin

Bausch Health Announces Third Quarter 2026 Results, Raises Guidance

October 28, 2026

  • Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period
  • GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million
  • GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period, an increase of 53%
  • Consolidated Adjusted EBITDA Attributable to Bausch Health1 of $1,305 million, up 32% over the prior year period

BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS

  • Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA1 growth, with 12% Reported and 8% Organic Revenue1 growth and 32% Adjusted EBITDA1 growth
  • Net Income increased $205 million over the prior year
  • Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations1
  • Raising full year 2026 Revenue, Adjusted EBITDA1, and Adjusted Cash Flows from Operations1 guidance

LAVAL, QC, October 28, 2026 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter.

"Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

The Company also announced that its Board of Directors has authorized a $50 million share repurchase program, with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027.

Third Quarter 2026 Revenue Performance

Total consolidated reported revenues were $2.94 billion for the third quarter of 2026, compared with $2.68 billion in the third quarter of 2025, an increase of $260 million, or 10%. Excluding the impact of acquisitions of $37 million and divestitures and discontinuations of $11 million, revenue increased 8% on an organic1 basis compared with the third quarter of 2025. The net impact of foreign exchange was de minimis in the quarter.

1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures and ratios to the most directly comparable GAAP measure.

Read More

View original release here: https://www.prnewswire.com/news-releases/bausch-health-announces-third-quarter-2026-results-raises-guidance-302922662.html?tc=eml_cleartime

<< Back to News Releases

Investor Inquiries
[email protected]

877-281-6642
514-856-3855 (Canada)

Media inquiries
[email protected]

848-264-0934

linkedIn Icon

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION **

Powered by Sitecore

Prompts

Bausch Health Companies Inc. (ticker BHC), listed in United States.

Company History

Date Change Detail
Jul 16, 2018 Renamed VALEANT PHARMACEUTICALS INTERNATIONAL, INC. → BAUSCH HEALTH COMPANIES INC.
Aug 2, 2010 Renamed BIOVAIL CORP → VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Nov 30, 2009 Renamed BIOVAIL CORP INTERNATIONAL → BIOVAIL CORP
Nov 2, 2001 Renamed BIOVAIL CORPORATION INTERNATIONAL → BIOVAIL CORP INTERNATIONAL
— Predecessor Predecessor Valeant Pharmaceuticals International (CIK 930184) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Bausch Health Companies Inc.

ETF Weight in ETF Shares Market value As of
DTAN 0.38% 9,716 $ 82.295K Nov 17, 2026
DFIS 0.05% 337,010 $ 2.78M Nov 12, 2026
DISV 0.03% 214,485 $ 1.77M Nov 12, 2026
DXIV 0.03% 7,943 $ 65.53K Nov 12, 2026
DFIC 0.01% 235,549 $ 1.943M Nov 12, 2026
AVDE 0.01% 132,116 $ 1.113M Nov 16, 2026
DFSI 0.01% 13,929 $ 114.914K Nov 12, 2026
DFAX 0.01% 120,510 $ 994.12K Nov 12, 2026
DFAI 0.00% 92,212 $ 760.486K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
BHC canonical Common share — US nyse 5.83 USD 2026-09-30
BHC Common share — CA tsx — —